Table 1.
Patient characteristics.
| AAV patients (n = 11) | Flow cytometry studies (n = 6) | |
|---|---|---|
| Demographics | ||
| Age | 59 (33–77) | 42 (33–77) |
| Male | 6 (55%) | 3 (50%) |
| Caucasian | 11 (100%) | 6 (100%) |
| ANCA associated vasculitis | ||
| GPA | 4 (36%) | 2 (33%) |
| MPA | 6 (55%) | 3 (50%) |
| eGPA | 1 (9%) | 1 (17%) |
| Immunology | ||
| ANCA immunofluorescence | ||
| c-ANCA | 3 (27%) | 1 (17%) |
| p-ANCA | 7 (64%) | 4 (67%) |
| negative | 1 (9%) | 1 (17%) |
| ELISA | ||
| PR3 | 4 (36%) | 2 (50%) |
| MPO | 6 (55%) | 4 (67%) |
| negative | 1 (9%) | 1 (17%) |
|
Low sensitive flow cytometry CD19+ B-cells (106/L) |
27 (0–311) | 183.5 (1–311) |
| Organ involvement | ||
| Constitutional symptoms | 6 (55%) | 3 (50%) |
| Mucocuteanous | 3 (27%) | 1 (17%) |
| Musculoskeletal | 4 (36%) | 2 (33%) |
| ENT | 6 (55%) | 2 (33%) |
| Renal | 6 (55%) | 3 (50%) |
| Respiratory | 7 (64%) | 3 (50%) |
| Cardiovascular | 1 (9%) | 1 (17%) |
| Central nervous system | 1 (9%) | 0 (0%) |
| Peripheral nervous system | 0 (0%) | 0 (0%) |
| Ophthalmology | 3 (27%) | 0 (0%) |
| Abdominal | 3 (27%) | 2 (33%) |
| Disease parameters | ||
| BVAS | 6 (0–30) | 11.5 (6–30) |
| VDI | 3 (0–12) | 0.5 (0–7) |
| Reason for treatment | ||
| New diagnosis | 4 (36%) | 4 (67%) |
| Relapse | 1 (9%) | 0 (0%) |
| Persistent disease | 2 (18%) | 2 (33%) |
| Maintenance treatment | 4 (36%) | 0 (0%) |
| Treatment | ||
| Rituximab | ||
| 2× 1,000 mg | 6 (55%) | 6 (100%) |
| 1× 500 mg | 5 (45%) | 0 (0%) |
| Methylprednisolone 3× 1,000 mg | 4 (36%) | 4 (67%) |
| Plasmapheresis | 1 (9%) | 1 (17%) |
| Cyclophosphamide (2× 500 mg) | 1 (9%) | 1 (17%) |
| High-dose corticosteroids | 5 (45%) | 5 (83%) |
| Previous remission-induction treatment | ||
| Rituximab | 5 (45%) | 0 (0%) |
| Cyclophosphamide oral | 3 (27%) | 1 (17%) |
| Cyclophosphamide IV | 2 (18%) | 0 (0%) |
For numerical values the median with (range) and for categorical values the frequency with percentages is shown.